UnitedHealth Group Incorporated, a leading health care and well-being company, reported its financial results for the third quarter of 2024 on October 15, 2024. The company announced revenues of $100.8 billion, an increase of $8.5 billion from the previous year, driven by growth in the number of people served by its Optum and UnitedHealthcare divisions. The quarter's earnings per share were $6.51, which included impacts from a cyberattack. Adjusted earnings per share were $7.15, accounting for business disruption impacts and excluding direct response costs. The company's full-year net earnings outlook was adjusted to $15.50 to $15.75 per share, reflecting the disposition of South American operations and cyberattack impacts. The adjusted net earnings outlook remains within the previously established range of $27.50 to $28.00 per share, despite absorbing...Show More

UnitedHealth Group Incorporated, a leading health care and well-being company, reported its financial results for the third quarter of 2024 on October 15, 2024. The company announced revenues of $100.8 billion, an increase of $8.5 billion from the previous year, driven by growth in the number of people served by its Optum and UnitedHealthcare divisions. The quarter's earnings per share were $6.51, which included impacts from a cyberattack. Adjusted earnings per share were $7.15, accounting for business disruption impacts and excluding direct response costs. The company's full-year net earnings outlook was adjusted to $15.50 to $15.75 per share, reflecting the disposition of South American operations and cyberattack impacts. The adjusted net earnings outlook remains within the previously established range of $27.50 to $28.00 per share, despite absorbing an estimated $0.75 per share of business disruption impacts. UnitedHealthcare's commercial domestic offerings grew by 2.4 million consumers year to date, and the company's Medicare Advantage plans for 2025 will reach 96% of eligible beneficiaries. Optum's revenue grew by $7.2 billion, led by Optum Health and Optum Rx. The company's operating cost ratio improved, and it returned over $9.6 billion to shareholders through dividends and share repurchases in the first nine months of 2024.